BTIG Research Has Lowered Expectations for Billiontoone (NASDAQ:BLLN) Stock Price

Billiontoone (NASDAQ:BLLN) had its price target lowered by research analysts at BTIG Research from $142.00 to $130.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential downside of 13.32% from the company’s current price.

A number of other research analysts have also recently commented on BLLN. Guggenheim initiated coverage on Billiontoone in a research note on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Billiontoone Trading Up 5.4%

Shares of Billiontoone stock opened at $149.97 on Thursday. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The firm has a market cap of $6.90 billion and a price-to-earnings ratio of 272.67. Billiontoone has a twelve month low of $61.96 and a twelve month high of $150.44. The business has a 50-day moving average price of $116.73 and a 200-day moving average price of $94.26.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The firm had revenue of $109.45 million for the quarter. Equities research analysts anticipate that Billiontoone will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Nancy Joann Johnson sold 801 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $124.91, for a total transaction of $100,052.91. Following the transaction, the insider directly owned 21,099 shares of the company’s stock, valued at approximately $2,635,476.09. This represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shan Riku Sakakibara sold 4,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $140.21, for a total value of $560,840.00. Following the transaction, the insider owned 200,000 shares in the company, valued at approximately $28,042,000. This trade represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 202,049 shares of company stock worth $23,496,861 over the last quarter. Insiders own 50.22% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Wasatch Advisors LP increased its position in shares of Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock valued at $62,160,000 after acquiring an additional 148,446 shares during the period. Thrive Wealth Management LLC acquired a new position in Billiontoone in the 2nd quarter worth approximately $240,000. Perceptive Advisors LLC lifted its stake in Billiontoone by 26.1% during the 1st quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock valued at $7,248,000 after acquiring an additional 19,000 shares during the period. Bank of America Corp DE increased its stake in shares of Billiontoone by 8,603.4% in the first quarter. Bank of America Corp DE now owns 12,707 shares of the company’s stock worth $1,003,000 after acquiring an additional 12,561 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Billiontoone by 151.8% in the first quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock valued at $2,408,000 after purchasing an additional 18,389 shares during the last quarter.

Key Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: BillionToOne reported second-quarter earnings of $0.15 per share, matching analysts’ consensus, on revenue of $109.45 million. The company also reiterated full-year 2026 revenue guidance of $450 million to $465 million, a range that brackets the $453.3 million consensus estimate. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
• Positive Sentiment: The company’s molecular-diagnostics platform and prenatal-testing business remain the central growth drivers. Investors may also be evaluating whether additional clinical applications can expand growth beyond prenatal screening. Does BillionToOne Have Another Major Growth Engine Beyond Prenatal Testing?
• Neutral Sentiment: The quarterly report did not provide a clear earnings-per-share outlook, limiting visibility into profitability for the remainder of 2026. The revenue forecast is essentially consistent with current expectations rather than a material upgrade.
• Negative Sentiment: CEO Oguzhan Atay sold a combined 45,000 shares worth approximately $6.17 million, reducing his ownership substantially. The transactions were made under a pre-arranged Rule 10b5-1 plan, which lessens their significance as a signal of near-term business concerns but may still create investor caution. SEC CEO Sale Filing
• Negative Sentiment: Another insider sold 4,000 shares for about $561,000. Meanwhile, BLLN’s valuation remains demanding, with a price-to-earnings ratio above 270, increasing sensitivity to any growth slowdown or disappointing guidance.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.